Chronic Urticaria

Allergy and immunology lost a pioneer last summer with the death of Marcus Maurer, MD, executive director of the Institute of Allergology at Charité University Medicine, Berlin.

Omalizumab is effective and safe for the treatment of chronic urticaria, demonstrating high discontinuation due to well-controlled disease, according to a study.

In order to better manage symptoms of atopic dermatitis, health care professionals must consider aggravating factors and systemic immunotherapy, according to a study published in the Chinese Medical Journal.

ANAHEIM, Calif. — The addition of leukotriene receptor antagonists to antihistamines improved urticaria severity with little to no impact on adverse events, according to a systematic review and meta-analysis.

Some patients who use omalizumab to treat their chronic urticaria may discontinue its use to reveal disease remission and avoid drug exposure, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Severing ties with difficult patients can be easier and less risky if they are given a “Patient’s Rights and Responsibilities” document as early as their initial registration, according to a speaker.

Nine percent of patients with chronic urticaria experienced exacerbations after getting a COVID-19 vaccination, according to a study published in The Journal of Allergy and Clinical Immunology.

A minority of patients with chronic urticaria experienced exacerbations after COVID-19 vaccination, with rare systemic reactions, according to a study published in The Journal of Allergy and Clinical Immunology.

Older patients with chronic urticaria have characteristics that are unique compared with younger patients, such as high rates of autoimmunity and malignancy, according to a study.